|
Real-time Estimate
Cboe BZX
15:59:58 2026-09-21 EDT
|
5-day change | 1st Jan Change | ||
| 1.815 USD | -4.47% |
|
-5.87% | -65.64% |
Company Valuation: Compass Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 309 | 633.5 | 198.8 | 199.5 | 955.1 | 342.2 | - | - |
| Change | - | 105.02% | -68.61% | 0.34% | 378.75% | -64.18% | - | - |
| Enterprise Value (EV) 1 | 309 | 633.5 | 198.8 | 72.78 | 955.1 | 192.2 | 209.2 | 226.2 |
| Change | - | 105.02% | -68.61% | -63.39% | 1,212.3% | -79.88% | 8.85% | 8.13% |
| P/E | -2.42x | -13.6x | -4.73x | -4.03x | -12.8x | -3.79x | -3.44x | -8.7x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.4x | -0.44x | -0.8x | -0.2x | -0.3x | 0.1x |
| Capitalization / Revenue | - | - | - | 235x | - | - | 15.3x | 2.74x |
| EV / Revenue | - | - | - | 85.6x | - | - | 9.34x | 1.81x |
| EV / EBITDA | -3.8x | -15.5x | -4x | -1.3x | -13.2x | -1.92x | -1.96x | -2.2x |
| EV / EBIT | -3.77x | -15.2x | -3.95x | -1.29x | -13.1x | -1.93x | -1.89x | -4.68x |
| EV / FCF | -14.3x | - | - | -1.62x | -19.4x | -2.42x | -2.15x | -6x |
| FCF Yield | -6.98% | - | - | -61.7% | -5.15% | -41.4% | -46.5% | -16.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.31 | -0.37 | -0.33 | -0.36 | -0.42 | -0.5007 | -0.5529 | -0.2185 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 0.85 | - | - | 22.39 | 124.7 |
| EBITDA 1 | -81.32 | -40.87 | -49.66 | -56.04 | -72.56 | -100.2 | -107 | -102.6 |
| EBIT 1 | -81.88 | -41.66 | -50.36 | -56.62 | -72.84 | -99.4 | -110.9 | -48.37 |
| Net income 1 | -82.18 | -39.22 | -42.49 | -49.38 | -66.49 | -94.04 | -109.8 | -45.82 |
| Net Debt 1 | - | - | - | -126.7 | - | -150 | -133 | -116 |
| Reference price 2 | 3.170 | 5.030 | 1.560 | 1.450 | 5.370 | 1.900 | 1.900 | 1.900 |
| Nbr of stocks (in thousands) | 97,472 | 125,938 | 127,455 | 137,589 | 177,862 | 180,088 | - | - |
| Announcement Date | 3/18/22 | 3/15/23 | 3/21/24 | 2/27/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.79x | - | -1.92x | - | 342M | |
| 20.78x | 7.3x | 14.73x | 1.43% | 70.88B | |
| 48.85x | 9.38x | 29.23x | 0.04% | 62.49B | |
| 30.44x | 6.47x | 16.8x | -.--% | 26.34B | |
| -73.25x | 14.16x | -68.28x | -.--% | 26.21B | |
| -14.7x | 5.35x | -6.73x | -.--% | 24.13B | |
| 28.25x | 5.33x | 17.72x | -.--% | 20.72B | |
| 45.45x | 16.69x | 33.86x | 0.33% | 15.69B | |
| 18.03x | 5.37x | 12.55x | -.--% | 14.46B | |
| -15.41x | 3481.82x | -17.8x | -.--% | 14.24B | |
| Average | 8.46x | 394.65x | 3.02x | 0.2% | 27.55B | |
| Weighted average by Cap. | 15.94x | 188.28x | 7.94x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CMPX Stock
- Valuation Compass Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
